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Transitional cell carcinoma of the ovaryTo the editors:
We recently read the report prepared by Yu et al entitled
“Primary ovary transitional cell carcinoma after renal trans-
plantation”1 with great interest. Transitional cell carcinoma
(TCC) of the ovary is a rare, recently recognized subtype of
epithelial ovarian cancer and is a type of cell that is frequently
found in the urinary tract1; therefore, accurately diagnosing
TCC in the ovaries as the primary or metastatic lesion is
important because the appropriate treatment choice could
differ depending on the initial diagnosis. In addition, a malig-
nant Brenner tumor of the ovary is very similar to primary
ovarian TCC, but these are different diseases with different
treatment protocols. In order to make a clearer and more
accurate differential diagnosis, in addition to identifying any
basic histological differences, immunohistochemical staining
may be helpful. We learned a lot from the authors’ effort
because they addressed some important concepts. For
example, the authors introduced four markersdCK7, CK20,
thrombomodulin, and uroplakin IIIdto help differentiate the
primary and metastatic lesions of ovarian TCC. The authors
also emphasized two points: (1) the presence of CK7þ/
CK20þ always indicates a urinary tract origin; and (2) ovarian
TCCs are negative for CK20, thrombomodulin, and uroplakin
III.1 However, in addition to the abovementioned immuno-
histochemical markers we would also like to introduce others,
including vimentin, CA-125, Wilms’ tumor protein (WT1),
and various estrogen receptors, because these markers are
positive in primary ovarian TCC but negative in urinary tract
TCC.2 We hope this information will help the readers under-
stand the characteristics of ovarian TCC.
We would, however, like to know which treatment regimen
Yu et al1 used to manage primary ovarian TCC, and we hope
to see further discussions regarding this issue. We would also
like to emphasize that this should not be considered an
argument against the excellent and successful management of
this patient’s condition that was provided by the authors. It is
well known that primary ovarian TCC has a better prognosis
than all other types of ovarian carcinomas following stan-
dardized chemotherapy.3 Higher survival rates can be ach-
ieved by using standard treatment options, such as surgical
resection followed by cisplatin-based chemotherapy,3 which
has been previously described by the authors.3 However, we1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.08.021would like some clarification regarding Dr. Yu’s chemo-
therapy regimen: specifically, the combination use of carbo-
platin (300 mg/m2) and gemcitabine (1000 mg/m2). Based on
our understanding of the guidelines provided by the National
Health Insurance Bureau of Taiwan, we should prescribe
a cisplatin-based regimen, which often includes the use of
cyclophosphamide. In one literature review, this combination
was popular and resulted in good therapeutic outcomes2; this
regimen might also have been appropriate for the authors’
patient because this patient was diagnosed as surgico-
pathological stage IIa. Of course, other combinations could
have been used to manage this patient’s condition. For
example, carboplatin plus paclitaxel is also good therapeutic
optionda recent report favored this combination for treating
all forms of epithelial ovarian cancers. We assume that the
authors’ use of gemcitabine and carboplatin might be based
on the presence of bladder cancer since the Cochrane Data-
base Systemic Review concluded that this combination is
beneficial for unresectable, locally advanced or metastatic
bladder cancer.4Yiu-Tai Li
Department of Obstetrics and Gynecology,
Kuo General Hospital, Tainan, Taiwan, ROC
Wen-Hsiang Su
Institute of Systems Biology and Bioinformatics,
National Central University, Tao-Yuan, Taiwan, ROC
Department of Obstetrics and Gynecology,
Yee-Zen Hospital, Tao-Yuan, Taiwan, ROC
Wen-Ling Lee*
Department of Medicine,
Cheng-Hsin General Hospital, Taipei, Taiwan, ROC
Department of Life Science,
National Central University, Tao-Yuan, Taiwan, ROC
*Corresponding author. Dr. Wen-Ling Lee,
Department of Medicine,
Cheng-Hsin General Hospital,
45, Cheng-Hsin Street, Taipei 112, Taiwan, ROC.
E-mail address: johnweiwang@hotmail.comhinese Medical Association. All rights reserved.
479Letter to the Editor / Journal of the Chinese Medical Association 74 (2011) 478e479References
1. Yu CC, Chen SL, Lian JD, Koo CL, Shih YT. Primary ovary transitional
cell carcinoma after renal transplantation. J Chin Med Assoc
2011;74:230e2.
2. Lin CH, Liu FS, Ho ES. Transitional cell carcinoma of the ovary. Taiwan
J Obstet Gynecol 2006;45:268e71.3. Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A.
Survival benefit for patients with advanced-stage transitional cell carci-
nomas vs. other subtypes of ovarian carcinoma after chemotherapy with
platinum and paclitaxel. Gynecol Oncol 2005;97:195e9.
4. Shelley M, Cleves A, Wilt TJ, Mason M. Gemcitabine for unresectable,
locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev
2011;4:CD008976.
